Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $36.5800 (6.12%) ($33.0500 - $36.8300) on Tue. Feb. 6, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.65% (three month average) | RSI | 53 | Latest Price | $36.5800(6.12%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.4% a day on average for past five trading days. | Weekly Trend | ADMS declines -3.6% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(25%) IBB(23%) IWM(19%) IWO(19%) QQQ(19%) | Factors Impacting ADMS price | ADMS will decline at least -1.825% in a week (0% probabilities). VIXM(-13%) UNG(-9%) BNDX(-9%) UUP(-8%) TLT(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.825% (StdDev 3.65%) | Hourly BBV | 0 () | Intraday Trend | 10.7% | | | |
|
Resistance Level | $37.83 | 5 Day Moving Average | $36.66(-0.22%) | 10 Day Moving Average | $38.42(-4.79%) | 20 Day Moving Average | $37.83(-3.3%) | To recent high | -14.2% | To recent low | 39% | Market Cap | $1.035b | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |